ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 132 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.88 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $0 | – | 0 | – | 0.00% | – |
| Q1 2021 | $0 | – | 0 | – | 0.00% | – |
| Q4 2020 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| Q3 2020 | $11,000 | – | 259 | – | 0.00% | – |
| Q2 2020 | $0 | – | 0 | – | 0.00% | – |
| Q1 2020 | $0 | – | 0 | – | 0.00% | – |
| Q4 2019 | $0 | – | 0 | – | 0.00% | – |
| Q3 2019 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
| Q3 2018 | $12,000 | -25.0% | 136 | 0.0% | 0.00% | -100.0% |
| Q2 2018 | $16,000 | +100.0% | 136 | 0.0% | 0.00% | – |
| Q1 2018 | $8,000 | 0.0% | 136 | 0.0% | 0.00% | – |
| Q4 2017 | $8,000 | +33.3% | 136 | 0.0% | 0.00% | – |
| Q3 2017 | $6,000 | +20.0% | 136 | 0.0% | 0.00% | – |
| Q2 2017 | $5,000 | +25.0% | 136 | 0.0% | 0.00% | – |
| Q1 2017 | $4,000 | -60.0% | 136 | -56.3% | 0.00% | – |
| Q4 2016 | $10,000 | +100.0% | 311 | +77.7% | 0.00% | – |
| Q3 2016 | $5,000 | -86.1% | 175 | -89.4% | 0.00% | -100.0% |
| Q2 2016 | $36,000 | -36.8% | 1,651 | -3.7% | 0.00% | -50.0% |
| Q4 2015 | $57,000 | – | 1,714 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 511,186 | $43,686,000 | 11.23% |
| GREAT POINT PARTNERS LLC | 210,400 | $17,981,000 | 2.80% |
| ARMISTICE CAPITAL, LLC | 456,000 | $38,970,000 | 2.34% |
| Matarin Capital Management, LLC | 210,208 | $17,964,376,000 | 1.16% |
| Sapphire Star Partners LP | 8,168 | $698,000 | 0.70% |
| Granahan Investment Management | 103,320 | $8,830,000 | 0.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 867,500 | $74,137,000 | 0.44% |
| 361 CAPITAL LLC | 19,040 | $1,627,000 | 0.35% |
| ALGERT GLOBAL LLC | 17,922 | $1,532,000 | 0.33% |
| AlphaMark Advisors, LLC | 9,310 | $796,000 | 0.32% |